Regeneron Reports Positive EYLEA HD Study Results

Regeneron Pharmaceuticals announces positive three-year results for EYLEA HD treatment in wAMD patients, leading to sustained vision improvements and longer dosing intervals. Investors should monitor Regeneron closely for its potential stock price impact.

Date: 09-02-2025

AI Rating: 7

Positive Study Results
Regeneron’s announcement regarding EYLEA HD shows significant promise. The study indicates that most patients maintained visual and anatomical improvements over three years of treatment while also benefiting from extended dosing intervals, reducing the treatment burden significantly.

Safety Concerns
While the results were positive, the report did mention common adverse effects like cataract and retinal hemorrhage, which could raise concerns among healthcare providers and patients about the long-term safety of the drug.

Regulatory Oversight
Continued regulatory obligations and pending civil proceedings involving the U.S. Department of Justice were also mentioned, which may pose challenges for Regeneron. This could create uncertainty regarding the company’s operational and financial future, which may impact their stock price negatively.

Insider and Congressional Trading
The report highlighted concerning trading activities, with no purchases but six sales from Congress members and numerous insider sales, potentially indicating a lack of confidence from those with more insight into the company. This could signal a bearish perspective from insiders regarding future stock performance.

Stocks: REGN